Aditxt is a biotech company. Co. is developing and commercializing technologies with a focus on monitoring and modulating the immune system. Co.'s portfolio includes the following programs: Adimune, which are immune modulation technologies designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies; and AditxtScore, which are immune monitoring technologies designed to provide a personalized comprehensive profile of the immune system. The ADTX average annual return since 2020 is shown above.
The Average Annual Return on the ADTX average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ADTX average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|